SLC5A2 and hydrops fetalis: In the context of HF, recent reports suggested that the SGLT2 inhibitors-mediated volume unloading and sustained improvement in the left ventricular filling pressure may contribute to the reduced risk of adverse CV outcomes, particularly HHF [70] although this mechanism was not supported by subanalysis of the EMPEROR-Reduced trial [71].